Details of the Drug Combination

General Information of Drug Combination (ID: DC5HS0D)

Drug Combination Name
LY2523355 AEE-788
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs LY2523355   DMCV602 AEE-788   DMEOS5K
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 14.704
Bliss Independence Score: 12.44
Loewe Additivity Score: 0.894
LHighest Single Agent (HSA) Score: 0.325

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LY2523355
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [2]
LY2523355 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Kinesin-like protein KIF11 (KIF11) TTTRP0H KIF11_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of AEE-788
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
AEE-788 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fibroblast growth factor receptor 2 (FGFR2) TTGJVQM FGFR2_HUMAN Inhibitor [5]
Fibroblast growth factor receptor 3 (FGFR3) TTST7KB FGFR3_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT01416389) A Study of LY2523355 in Patients With Breast Cancer. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7643).
4 Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
5 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.